Imiquimod for the treatment of oral leukoplakia: A two-center retrospective study.

Autor: Sroussi H; Brigham and Women's Hospital, Boston, Massachusetts, USA.; Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Harvard School of Dental Medicine, Boston, Massachusetts, USA., Villa A; Miami Cancer Institute, Miami, Florida, USA.; Department of Orofacial Sciences, UCSF, San Francisco, California, USA., Alhadlaq MA; Brigham and Women's Hospital, Boston, Massachusetts, USA.; Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Harvard School of Dental Medicine, Boston, Massachusetts, USA., Ikeda K; Brigham and Women's Hospital, Boston, Massachusetts, USA.; Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Harvard School of Dental Medicine, Boston, Massachusetts, USA., Veluppillai S; Department of Orofacial Sciences, UCSF, San Francisco, California, USA., Treister N; Brigham and Women's Hospital, Boston, Massachusetts, USA.; Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Harvard School of Dental Medicine, Boston, Massachusetts, USA., Monreal AV; Herman Ostrow School of Dentistry of USC, Los Angeles, California, USA., Vacharotayangul P; Brigham and Women's Hospital, Boston, Massachusetts, USA.; Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Harvard School of Dental Medicine, Boston, Massachusetts, USA., Lodolo M; Department of Orofacial Sciences, UCSF, San Francisco, California, USA., Woo SB; Brigham and Women's Hospital, Boston, Massachusetts, USA.; Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Harvard School of Dental Medicine, Boston, Massachusetts, USA.
Jazyk: angličtina
Zdroj: Oral diseases [Oral Dis] 2024 Jul 15. Date of Electronic Publication: 2024 Jul 15.
DOI: 10.1111/odi.15069
Abstrakt: Objectives: We aimed to assess the effectiveness of the use of topical imiquimod for the management of oral leukoplakia (OL).
Methods: This was a retrospective study. Medical chart reviews were conducted to identify patients with biopsy-proven OL treated with topical 5% imiquimod. Data included OL characteristics, histopathological diagnosis, treatment outcome, and adverse events (AEs). Treatment response was assessed by measuring the percentage reduction in the size of OL lesions.
Results: 33 patients (51.5% females; median age: 65 years) with 38 lesions were included. OLs were either localized (23.7%) or multifocal lesions (76.3%), with the majority on the gingiva (86.8%). Pretreatment histopathological diagnoses were dysplasia in 84.2% and nonreactive hyperkeratosis in 15.8%. Most regimens consisted of 60-minute applications, 5-days-a-week, for 6 weeks. At the end of treatment, 81.6% of 38 lesions showed a reduction in size with 68.4% exhibiting ≥50% reduction in size, and 42.1% exhibiting complete resolution. Application site reactions were the most common with pain/soreness/sensitivity occurring in 86.8%. Fatigue was the most frequently reported systemic AE (28.9%).
Conclusion: Two-thirds of OL lesions had ≥50% reduction in size. Most AEs were temporary and resolved upon treatment discontinuation. Prospective studies are needed to further assess Imiquimod's effectiveness in OL management.
(© 2024 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: